SG11202104404XA - Erk inhibitors and uses thereof - Google Patents

Erk inhibitors and uses thereof

Info

Publication number
SG11202104404XA
SG11202104404XA SG11202104404XA SG11202104404XA SG11202104404XA SG 11202104404X A SG11202104404X A SG 11202104404XA SG 11202104404X A SG11202104404X A SG 11202104404XA SG 11202104404X A SG11202104404X A SG 11202104404XA SG 11202104404X A SG11202104404X A SG 11202104404XA
Authority
SG
Singapore
Prior art keywords
erk inhibitors
erk
inhibitors
Prior art date
Application number
SG11202104404XA
Other languages
English (en)
Inventor
Corey Reeves
Brendan O'boyle
Justin Hilf
Dylan Conklin
Martina Mcdermott
Neil O'brien
Michael Palazzolo
Dennis Slamon
Steven WITTENBERGER
Oliver Loson
Michael Bartberger
Brian Stoltz
Original Assignee
California Inst Of Techn
1200 Pharma Llc
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by California Inst Of Techn, 1200 Pharma Llc, Univ California filed Critical California Inst Of Techn
Publication of SG11202104404XA publication Critical patent/SG11202104404XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11202104404XA 2018-11-16 2019-11-15 Erk inhibitors and uses thereof SG11202104404XA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862768565P 2018-11-16 2018-11-16
US201962908965P 2019-10-01 2019-10-01
PCT/US2019/061750 WO2020102686A1 (fr) 2018-11-16 2019-11-15 Inhibiteurs d'erk et leurs utilisations

Publications (1)

Publication Number Publication Date
SG11202104404XA true SG11202104404XA (en) 2021-05-28

Family

ID=70730924

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202104404XA SG11202104404XA (en) 2018-11-16 2019-11-15 Erk inhibitors and uses thereof

Country Status (12)

Country Link
US (1) US20220002294A1 (fr)
EP (1) EP3880677A4 (fr)
JP (1) JP2022507514A (fr)
KR (1) KR20210130701A (fr)
CN (1) CN113423707A (fr)
AU (1) AU2019381808A1 (fr)
BR (1) BR112021009430A2 (fr)
CA (1) CA3119988A1 (fr)
IL (1) IL283106A (fr)
MX (1) MX2021005171A (fr)
SG (1) SG11202104404XA (fr)
WO (1) WO2020102686A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4212531A1 (fr) 2022-01-14 2023-07-19 AGV Discovery Dérivés d'azaindole et leur utilisation en tant qu'inhibiteurs de kinase erk

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1756108A2 (fr) * 2004-04-02 2007-02-28 Vertex Pharmaceuticals Incorporated Azaindoles utiles en tant qu'inhibiteurs de la proteine serine/threonine kinase superhelice de la famille rho (rock) et d'autres proteines kinases
CN101228160A (zh) * 2004-06-30 2008-07-23 沃泰克斯药物股份有限公司 可用作蛋白激酶抑制剂的吖吲哚
CN102603581B (zh) * 2005-06-22 2015-06-24 普莱希科公司 作为蛋白质激酶抑制剂的吡咯并[2,3-b]吡啶衍生物
DE102008031517A1 (de) * 2008-07-03 2010-01-07 Merck Patent Gmbh Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
EP2318407B1 (fr) * 2008-07-23 2013-01-02 Vertex Pharmaceuticals Incorporated Inhibiteurs de la pyrazolopyridine kinase
DE102009043260A1 (de) * 2009-09-28 2011-04-28 Merck Patent Gmbh Pyridinyl-imidazolonderivate
DE102009060174A1 (de) * 2009-12-23 2011-06-30 Merck Patent GmbH, 64293 Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
WO2012094313A1 (fr) * 2011-01-04 2012-07-12 Kinentia Biosciences Llc Dérivés de pyrazole à titre d'inhibiteurs d'erk
WO2013052355A1 (fr) * 2011-10-03 2013-04-11 Merck Sharp & Dohme Corp. Azaindoles en tant qu'inhibiteurs de janus kinase
RU2015114936A (ru) * 2012-10-16 2016-12-10 Ф. Хоффманн-Ля Рош Аг Ингибиторы серин/треонинкиназы
BR112015016580A2 (pt) * 2013-01-11 2017-07-11 Fujifilm Corp composto heterocíclico contendo nitrogênio ou sal deste
RS57058B1 (sr) * 2013-10-03 2018-05-31 Kura Oncology Inc Ekr inhibitori i postupci primene
WO2016026078A1 (fr) * 2014-08-19 2016-02-25 Changzhou Jiekai Pharmatech Co., Ltd. Composés hétérocycliques utilisés comme inhibiteurs de erk
CA2973597A1 (fr) * 2015-01-23 2016-07-28 Confluence Life Sciences, Inc. Inhibiteurs d'itk heterocycliques pour traiter l'inflammation et le cancer
EP3170822A1 (fr) * 2015-11-18 2017-05-24 AGV Discovery Dérivés d'azaindole et leur utilisation en tant qu'inhibiteurs de kinase erk
CN107973783A (zh) * 2016-10-21 2018-05-01 正大天晴药业集团股份有限公司 作为erk抑制剂的苯胺嘧啶衍生物
CN108948002A (zh) * 2017-05-19 2018-12-07 厦门大学 五元并六元氮杂芳环类化合物、其制备方法、药用组合物及其应用

Also Published As

Publication number Publication date
MX2021005171A (es) 2021-10-01
BR112021009430A2 (pt) 2021-08-17
KR20210130701A (ko) 2021-11-01
CA3119988A1 (fr) 2020-05-22
AU2019381808A1 (en) 2021-05-27
EP3880677A4 (fr) 2022-06-22
CN113423707A (zh) 2021-09-21
JP2022507514A (ja) 2022-01-18
WO2020102686A1 (fr) 2020-05-22
IL283106A (en) 2021-06-30
US20220002294A1 (en) 2022-01-06
EP3880677A1 (fr) 2021-09-22

Similar Documents

Publication Publication Date Title
IL282487A (en) TYK2 inhibitors and their use
IL271999A (en) TYK2 inhibitors and uses thereof
IL289612A (en) hpk1 inhibitors and uses thereof
ZA202002172B (en) Pde9 inhibitor and use thereof
GB201605126D0 (en) Inhibitors and their uses
IL270330B (en) Beta-lactamase inhibitors and their uses
EP3471726A4 (fr) Inhibiteurs de cxcr4 et leurs utilisations
IL283409A (en) tyk2 inhibitors and uses thereof
IL282090A (en) tyk2 inhibitors and uses thereof
EP3572400C0 (fr) Inhibiteur de l'ezh2 et son utilisation
PT3621694T (pt) Inibidores de lrrc33 e sua utilização
IL272649B (en) AHR inhibitors and their uses
IL282350A (en) Bernani-RGMC inhibitors and their use
IL279276A (en) ERK inhibitor and use thereof
IL291217A (en) usp30 inhibitors and their uses
IL263949A (en) Complement inhibitors and their uses
ZA201905934B (en) Dual magl and faah inhibitors
IL292198A (en) Tim-3 inhibitors and their uses
GB201820088D0 (en) Opitical devices and methods
EP3585809A4 (fr) Inhibiteurs de thiol isomérases et leur utilisation
IL283106A (en) erk inhibitors and their uses
EP3704104A4 (fr) Inhibiteurs d'irak4 et leurs utilisations
EP3463371A4 (fr) Inhibiteurs de ku et leur utilisation
IL280408A (en) CDK inhibitors and uses thereof
EP3892619A4 (fr) INHIBITEUR SÉLECTIF DE PI3Ko ET SON UTILISATION